40-301 : Special Drug Use-Results Survey of ADLUMIZ

ABSTRACT: Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors [Efficacy]Body weight increasing effect and appetite increasing effect

DISEASE(S): Cancer Cachexia: Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Cancer, Large Intestine Canc

PROVIDER: 2613087 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR